Earth Science Tech (ETST) Net Income towards Common Stockholders (2011 - 2026)
Earth Science Tech (ETST) posted Net Income towards Common Stockholders of $1.3 million for Q1 2026, up 41.48% on a QoQ basis from $910368.0 in Q4 2025, and up 9.84% year-over-year from $1.2 million in Q1 2025.
Earth Science Tech (ETST) Net Income towards Common Stockholders (2011 - 2026) Analysis & Trends
Earth Science Tech's Net Income towards Common Stockholders history runs 15 years deep, the most recent figure standing at $1.3 million for Q1 2026.
- Quarterly Net Income towards Common Stockholders rose 9.84% year-over-year to $1.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.6 million (up 10.67% YoY) and the FY2026 annual result came in at $3.6 million, up 10.67% from the prior year.
- Net Income towards Common Stockholders was $1.3 million for Q1 2026 at Earth Science Tech, up from $910368.0 in the prior quarter.
- Across five years, Net Income towards Common Stockholders topped out at $1.3 million in Q1 2026 and bottomed at -$235509.0 in Q1 2023.
- A 5-year average of $430719.9 and a median of $229324.0 in 2024 frame the typical range for Net Income towards Common Stockholders.
- Annual changes were most pronounced in 2023 — Net Income towards Common Stockholders tumbled 667.61% — and 2024, when it jumped 3123.53%.
- Earth Science Tech's Net Income towards Common Stockholders stood at $98464.0 in 2022, then jumped by 128.96% to $225443.0 in 2023, then slipped by 8.44% to $206411.0 in 2024, then jumped by 341.05% to $910368.0 in 2025, then surged by 41.48% to $1.3 million in 2026.
- Business Quant data shows ETST's Net Income towards Common Stockholders at $1.3 million in Q1 2026, $910368.0 in Q4 2025, and $945897.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.91 Bn | 88.04 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.91 Bn | 32.17 Bn | 1.97 Bn | 370.00 Mn |
| 3 | Zoetis | 32.54 Bn | 30.60 Bn | 1.62 Bn | 601.00 Mn |
| 4 | Takeda Pharmaceutical | 27.54 Bn | 23.48 Bn | 4.39 Bn | -2.35 Bn |
| 5 | United Therapeutics | 23.05 Bn | 20.89 Bn | 648.10 Mn | 274.90 Mn |
| 6 | RedHill Biopharma | 21.48 Bn | 21.48 Bn | - | - |
| 7 | Viatris | 20.44 Bn | 18.64 Bn | 1.16 Bn | 176.40 Mn |
| 8 | Neurocrine Biosciences | 17.82 Bn | 16.50 Bn | 800.70 Mn | 197.90 Mn |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn | 57.00 Mn |
| 10 | Earth Science Tech | 32.24 Mn | 30.08 Mn | 6.27 Mn | 1.29 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.29 Mn |
| Dec 31, 2025 | 910,368.00 |
| Sep 30, 2025 | 945,897.00 |
| Jun 30, 2025 | 456,714.00 |
| Mar 31, 2025 | 1.17 Mn |
| Dec 31, 2024 | 206,411.00 |
| Sep 30, 2024 | 798,368.00 |
| Jun 30, 2024 | 1.08 Mn |
| Mar 31, 2024 | 229,324.00 |
| Dec 31, 2023 | 225,443.00 |
| Sep 30, 2023 | 444,581.00 |
| Jun 30, 2023 | -35,596.00 |
| Mar 31, 2023 | -235,509.00 |
| Dec 31, 2022 | 98,464.00 |
| Sep 30, 2022 | -73,678.00 |
| Jun 30, 2022 | -154,682.00 |
| Mar 31, 2022 | -30,681.00 |
| Dec 31, 2021 | -115,048.00 |
| Sep 30, 2021 | 3.34 Mn |
| Jun 30, 2021 | -22,410.00 |